Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that Kuvan (sapropterin dihydrochloride), indicated for the treatment of hyperphenylalaninaemia due to phenylketonuria or tetrahydrobiopterin deficiency, is now commercially available in Europe.
The details can be read here.
No comments:
Post a Comment